EA201990056A1 - COMPOSITION ANTI-α4β7 ANTIBODIES - Google Patents
COMPOSITION ANTI-α4β7 ANTIBODIESInfo
- Publication number
- EA201990056A1 EA201990056A1 EA201990056A EA201990056A EA201990056A1 EA 201990056 A1 EA201990056 A1 EA 201990056A1 EA 201990056 A EA201990056 A EA 201990056A EA 201990056 A EA201990056 A EA 201990056A EA 201990056 A1 EA201990056 A1 EA 201990056A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- compositions
- antibodies
- composition anti
- provides
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Описаны композиции антител, включающие смесь анти-α4β7 антитела, антиоксиданта или хелатирующего агента и по меньшей мере одной свободной аминокислоты. Раскрытые композиции могут обладать улучшенной стабильностью, пониженным образованием агрегатов или обоими этими характеристиками. Настоящее изобретение дополнительно предусматривает безопасный режим дозирования таких композиций антител, который может легко соблюдаться и который обеспечивает терапевтически эффективное количество анти-α4β7 антитела in vivo.Antibody compositions are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or a chelating agent and at least one free amino acid. The disclosed compositions may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosage regimen for such antibody compositions that can be readily observed and which provides a therapeutically effective amount of an anti-α4β7 antibody in vivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544054P | 2011-10-06 | 2011-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990056A1 true EA201990056A1 (en) | 2019-08-30 |
Family
ID=54359602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990056A EA201990056A1 (en) | 2011-10-06 | 2012-05-02 | COMPOSITION ANTI-α4β7 ANTIBODIES |
Country Status (2)
| Country | Link |
|---|---|
| EA (1) | EA201990056A1 (en) |
| TN (1) | TN2013000455A1 (en) |
-
2012
- 2012-05-02 EA EA201990056A patent/EA201990056A1/en unknown
-
2013
- 2013-10-31 TN TNP2013000455A patent/TN2013000455A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2013000455A1 (en) | 2015-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201391613A1 (en) | COMPOSITION ANTI-α4β7 ANTIBODIES | |
| PH12020500336A1 (en) | FORMULATION FOR ANTI-a4á7 ANTIBODY | |
| EA201491644A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EA201390145A1 (en) | CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS | |
| MX351414B (en) | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer. | |
| EA201691590A1 (en) | BENZIMIDAZOL-2-AMINES AS MIDHI INHIBITORS | |
| PH12014501410A1 (en) | Compositions and methods for antibodies targeting factor p | |
| EA201590887A1 (en) | COMPOSITION | |
| EA201490756A1 (en) | CITRAMID RAZAGLININA | |
| EA201490395A1 (en) | METHOD FOR OBTAINING PHARMACEUTICAL COMPOSITIONS CONTAINING FINGOLIMOD | |
| MX2019012375A (en) | Lfa-1 inhibitor formulations. | |
| PL401632A1 (en) | Pharmaceutical composition comprising an ACE inhibitor and a calcium channel blocker, a method for its preparation and the dosage unit comprising the composition | |
| EA201990056A1 (en) | COMPOSITION ANTI-α4β7 ANTIBODIES | |
| UA112984C2 (en) | COMPOSITION OF ANTI-α4β7 ANTIBODY | |
| EA201992881A2 (en) | ANTI-47 ANTIBODY COMPOSITION | |
| NZ740726A (en) | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |